(Q38093143)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Matthew A Cantrell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Jordan Baye

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

language of work or name

English

0 references

publication date

25 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

639-649

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia

27 February 2020

cites work

1 reference

The urologist view of BPH progression: results of an international survey

21 January 2018

1 reference

Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.

21 January 2018

1 reference

Watchful waiting in benign prostatic hyperplasia

21 January 2018

1 reference

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

21 January 2018

1 reference

Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies

21 January 2018

1 reference

Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group

21 January 2018

1 reference

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

21 January 2018

1 reference

The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study

21 January 2018

1 reference

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract

21 January 2018

1 reference

Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction

21 January 2018

1 reference

The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors

21 January 2018

1 reference

Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue

21 January 2018

1 reference

Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS.

21 January 2018

1 reference

Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk

21 January 2018

1 reference

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action

21 January 2018

1 reference

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

21 January 2018

1 reference

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

21 January 2018

1 reference

Sildenafil influences lower urinary tract symptoms.

21 January 2018

1 reference

Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction.

21 January 2018

1 reference

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

21 January 2018

1 reference

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study

21 January 2018

1 reference

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.

21 January 2018

1 reference

Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study

21 January 2018

1 reference

Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms.

21 January 2018

1 reference

Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

21 January 2018

1 reference

Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects

21 January 2018

1 reference

Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men.

21 January 2018

1 reference

Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo

21 January 2018

1 reference

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

21 January 2018

1 reference

Time course of the interaction between tadalafil and nitrates

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529917%20AND%20SRC:MED&resulttype=core&format=json